TW200612975A - Permucosal composition and method of improving permucosal absorption - Google Patents
Permucosal composition and method of improving permucosal absorptionInfo
- Publication number
- TW200612975A TW200612975A TW094131630A TW94131630A TW200612975A TW 200612975 A TW200612975 A TW 200612975A TW 094131630 A TW094131630 A TW 094131630A TW 94131630 A TW94131630 A TW 94131630A TW 200612975 A TW200612975 A TW 200612975A
- Authority
- TW
- Taiwan
- Prior art keywords
- mucosa
- permucosal
- composition
- improving
- absorption
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000004877 mucosa Anatomy 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 1
- 210000001156 gastric mucosa Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004268891 | 2004-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200612975A true TW200612975A (en) | 2006-05-01 |
| TWI291874B TWI291874B (https=) | 2008-01-01 |
Family
ID=36059983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094131630A TW200612975A (en) | 2004-09-15 | 2005-09-14 | Permucosal composition and method of improving permucosal absorption |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080075691A1 (https=) |
| EP (1) | EP1790351A4 (https=) |
| JP (1) | JPWO2006030730A1 (https=) |
| KR (1) | KR20070057932A (https=) |
| CN (1) | CN101018560A (https=) |
| AR (1) | AR050937A1 (https=) |
| AU (1) | AU2005283512A1 (https=) |
| BR (1) | BRPI0515301A (https=) |
| CA (1) | CA2577336A1 (https=) |
| MX (1) | MX2007003062A (https=) |
| RU (1) | RU2007114068A (https=) |
| TW (1) | TW200612975A (https=) |
| WO (1) | WO2006030730A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658204B2 (en) * | 2007-03-30 | 2014-02-25 | Otsuka Pharmaceutical Co., Ltd. | Transpulmonary liposome for controlling drug arrival |
| EP2253326B1 (en) * | 2008-02-28 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
| JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
| CN110312937B (zh) | 2017-01-19 | 2023-01-10 | 和田孝一郎 | 诊断肠黏膜通透性的诊断药、诊断方法及诊断装置 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1261264A (en) * | 1984-11-29 | 1989-09-26 | Shigeo Suzuki | Immunopotentiating agents and method |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH11116499A (ja) * | 1997-10-16 | 1999-04-27 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有した経口投与用ナノスフェア |
| GB9725084D0 (en) * | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| JP3041799B1 (ja) * | 1998-09-29 | 2000-05-15 | 株式会社微生物化学研究所 | 新規なアジュバント及びそれを用いたワクチン |
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| IL131074A0 (en) * | 1999-07-23 | 2001-03-19 | Polygene Ltd | A biodegradable polycation composition for delivery of an anionic macromolecule |
| US6773723B1 (en) * | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
| AU2002210407A1 (en) * | 2000-10-27 | 2002-05-06 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
| NO317654B1 (no) * | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav. |
| DE102004040243A1 (de) * | 2003-08-22 | 2005-03-17 | Heppe, Katja, Dipl.-Biotechnol. | Transportsystem auf Chitosanbasis |
| GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
-
2005
- 2005-09-12 RU RU2007114068/15A patent/RU2007114068A/ru not_active Application Discontinuation
- 2005-09-12 JP JP2006535871A patent/JPWO2006030730A1/ja active Pending
- 2005-09-12 KR KR1020077008268A patent/KR20070057932A/ko not_active Ceased
- 2005-09-12 CA CA002577336A patent/CA2577336A1/en not_active Abandoned
- 2005-09-12 AU AU2005283512A patent/AU2005283512A1/en not_active Abandoned
- 2005-09-12 BR BRPI0515301-8A patent/BRPI0515301A/pt not_active IP Right Cessation
- 2005-09-12 US US11/662,094 patent/US20080075691A1/en not_active Abandoned
- 2005-09-12 WO PCT/JP2005/016739 patent/WO2006030730A1/ja not_active Ceased
- 2005-09-12 CN CNA2005800308628A patent/CN101018560A/zh active Pending
- 2005-09-12 MX MX2007003062A patent/MX2007003062A/es unknown
- 2005-09-12 EP EP05782391A patent/EP1790351A4/en not_active Withdrawn
- 2005-09-14 TW TW094131630A patent/TW200612975A/zh not_active IP Right Cessation
- 2005-09-15 AR ARP050103852A patent/AR050937A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080075691A1 (en) | 2008-03-27 |
| WO2006030730A1 (ja) | 2006-03-23 |
| CA2577336A1 (en) | 2006-03-23 |
| TWI291874B (https=) | 2008-01-01 |
| EP1790351A8 (en) | 2007-10-10 |
| AR050937A1 (es) | 2006-12-06 |
| RU2007114068A (ru) | 2008-10-27 |
| AU2005283512A1 (en) | 2006-03-23 |
| EP1790351A1 (en) | 2007-05-30 |
| CN101018560A (zh) | 2007-08-15 |
| JPWO2006030730A1 (ja) | 2008-05-15 |
| EP1790351A4 (en) | 2009-11-04 |
| MX2007003062A (es) | 2007-05-21 |
| BRPI0515301A (pt) | 2008-07-15 |
| KR20070057932A (ko) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7166575B2 (en) | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity | |
| CA2045472C (en) | Drug delivery compositions | |
| ES2365648T3 (es) | Administración oral de una calcitonina. | |
| WO2004003145A2 (en) | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds | |
| WO2003000018A2 (en) | Dopamine agonist formulations for enhanced central nervous system delivery | |
| RU2011126239A (ru) | Фармацевтическая композиция, составленная для локального нанесения на поверхность барьера эпителиальной ткани, содержащая антитела, которые проходят через этот барьер | |
| JP2009537143A5 (https=) | ||
| RU2009111391A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| WO2003040398A3 (en) | Proteins stabilized with polysaccharide gums | |
| WO2003028757A1 (en) | Novel method of inducing antigen-specific t cells | |
| AU2018360382A1 (en) | Oral delivery of GLP-1 peptide analogs | |
| EP2311871A3 (en) | IL-1 antagonist stable liquid formulation | |
| TW200612975A (en) | Permucosal composition and method of improving permucosal absorption | |
| WO2003037272A3 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| DK168273B1 (da) | Anvendelse af cyclopeptidhjælpestoffer eller fysiologisk acceptable salte deraf som resorptionsfremmende stoffer af peptider og proteiner ved påføring på slimhinder samt farmaceutisk præparat indeholdende disse hjælpestoffer og fremgangsmåde til fremstilling af præparatet | |
| SE0401631L (sv) | Ny sammansättning | |
| Bayley et al. | The Transmucosal Absorption of Recombinant Human Interferon‐α B/D Hybrid in the Rat and Rabbit | |
| US20230218727A1 (en) | Thrombin c-terminal peptides to treat corona viral infections | |
| CA3180205A1 (en) | Use of surfactant protein d to treat viral infections | |
| WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
| WO2004023979A3 (en) | Mucus formulation for mucosal surfaces and uses thereof | |
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 | |
| JP7217760B2 (ja) | 急性呼吸不全の治療および／または予防の使用のための抗分泌因子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |